Related Experiment Video
Updated: May 25, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Factor V Leiden mutation and its impact on pregnancy complications
L'ubica Hammerová1, Ján Chabada, Juraj Drobný
11st Department of Gynaecology and Obstetrics, Comenius University, Faculty of Medicine University Hospital, Bratislava, Slovakia. hammerova@gmail.com
Acta Medica (Hradec Kralove)
|January 19, 2012
Summary
The factor V Leiden mutation (FVL) in pregnant women did not increase adverse outcomes. This study found no significant impact on preeclampsia or other major complications, suggesting FVL carriership is safe for pregnancy.
Area of Science:
- Reproductive Medicine
- Genetics
- Obstetrics
Background:
- Factor V Leiden (FVL) mutation is a common inherited thrombophilia.
- Its role in adverse pregnancy outcomes requires further clarification.
- Understanding FVL's impact is crucial for maternal and fetal health management.
Purpose of the Study:
- To investigate the association between heterozygous factor V Leiden mutation and adverse pregnancy outcomes.
- To analyze the frequency of placenta-mediated complications in FVL carriers.
- To compare pregnancy outcomes between FVL carriers and a control group.
Main Methods:
- Prospective observational study design.
- Comparison of 11 heterozygous FVL carriers with 41 non-carrier controls.
- Analysis of placenta-mediated complications and delivery outcomes.
Main Results:
- No venous thromboembolism occurred in any pregnancy.
- Gestational age at delivery and birth weight deviation showed minor significant differences.
- Higher incidence of blood loss >1000 ml observed in the control group, not FVL carriers.
Conclusions:
- Maternal heterozygous FVL mutation did not elevate the risk of preeclampsia.
- Adverse pregnancy outcomes like placental abruption were infrequent.
- The study provides evidence that FVL carriership does not increase the risk of adverse pregnancy outcomes.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:19Mitral Valve Prolapse III: Nursing Management
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...